Barinthus Biotherapeutics plc

Healthcare · Biotechnology · United States

Last price 0.7401 USD (At close: Sep 8, 2026) · Market cap 30.23M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with...